Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road.

ABSTRACT: Although new-generation antimicrobials, in particular β-lactam/β-lactamase inhibitors, have largely replaced polymyxins in carbapenem-resistant Gram-negative bacterial infections, polymyxins are still needed for carbapanem-resistant Acinetobacter baumannii infections and in settings where novel agents are not readily available. Despite their potent in vitro activity, the clinical utility of polymyxins is significantly limited by their pharmacokinetic properties and nephrotoxicity risk. There is significant interest, therefore, in developing next-generation polymyxins with activity against colistin-resistant strains and lower toxicity than existing polymyxins. In this review, we aim to present the antibacterial activity mechanisms, in vitro and in vivo efficacy data, and toxicity pro

SUBMITTER: Aslan AT 

PROVIDER: S-EPMC9774142 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature